02/04/13 -- International Stem Cell Corporation (OTCQB: ISCO) <br />(www.internationalstemcell.com) (ISCO or the Company) a California-based biotechnology <br />company, today announced positive 12-week results from its pre-clinical in vivo <br />Parkinson's disease study. The primary goal of this behavioral study was to demonstrate <br />the therapeutic benefits of neuronal cells derived from human parthenogenetic stem cell <br />(hpSC) line in a rat model of Parkinson's disease (PD).
